NCT03644732 Atlas of Human Cognition by SEEG (MAPCOG-SEEG)
| NCT ID | NCT03644732 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Refractory Epilepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2018-04-05 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2018-04-05 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of MAPCOG\_SEEG is to create a database including brain recordings of cognition performed in clinical routine in patients during the pre-surgical SEEG assessment. This aims to be able to propose the first atlas of human cognition with a high temporal and spatial resolution.
Eligibility Criteria
Inclusion Criteria: * Drug-resistant focal epilepsy * Justified SEEG exploration in the context of presurgical assessment of epilepsy * Written non-opposition to study participation * Intellectual capacities compatible with the compliance in the cognitive tasks Exclusion Criteria: * Major Patient undergoing a legal protection measure or patient deprived of liberty as a result of a judicial or administrative decision * Impossibility of collecting information on exposure (recent arrival in France, foreign language, etc.) * Pregnant women (Contraindication to SEEG exploration)
Contact & Investigator
Philippe Kahane, MD/PhD
PRINCIPAL INVESTIGATOR
University Hospital, Grenoble
Frequently Asked Questions
Who can join the NCT03644732 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Refractory Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03644732 currently recruiting?
Yes, NCT03644732 is actively recruiting participants. Contact the research team at pkahane@chu-grenoble.fr for enrollment information.
Where is the NCT03644732 trial being conducted?
This trial is being conducted at Grenoble, France, Nancy, France, Paris, France, Rennes, France.
Who is sponsoring the NCT03644732 clinical trial?
NCT03644732 is sponsored by University Hospital, Grenoble. The principal investigator is Philippe Kahane, MD/PhD at University Hospital, Grenoble. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.